Decreased cytokeratin 7 expression correlates with the progression of cervical squamous cell carcinoma and poor patient outcomes. Issue 11 (9th September 2019)

• Record Type: Journal Article
• Authors: Hashiguchi, Mariko; Masuda, Masanori; Kai, Keita; Nakao, Yoshifumi; Kawaguchi, Atsushi; Yokoyama, Masatoshi; Aishima, Shinichi
• Is Part Of: Journal of obstetrics and gynaecology research. Volume 45:Issue 11(2019)
• Page Start: 2228
• Page End: 2236
• Publication Date: 2019-09-09
• Subjects: cervical cancer -- CK17 -- CK7 -- podoplanin -- squamous cell carcinoma; Gynecology -- Periodicals; Obstetrics -- Periodicals; 618.1005
• DOI: 10.1111/jog.14108
• Languages: English
• ISSNs: 1341-8076

Abstract

Abstract: Aim: To identify potential biomarkers for tumor progression and patient outcomes in cervical squamous cell carcinoma. Methods: We examined the expressions of CK7 and CK17 as potential markers of the squamo‐columnar junction, and podoplanin as a basal cell marker using surgical and biopsy samples of patients in grade 3 cervical intraepithelial neoplasia ( n = 30), operable invasive carcinoma (OP group, n = 53) and inoperable invasive carcinoma before radiotherapy and/or chemotherapy (RC group, n = 76). Results: The positive rates of CK7 and podoplanin in invasive carcinoma were significantly lower than those in grade 3 cervical intraepithelial neoplasia ( P = 0.001, P < 0.0001). The positive rates of CK7 and podoplanin in the RC group were significantly lower than those in the OP group ( P < 0.0001, P = 0.04), while CK17 expression showed significantly higher positivity in the RC group than in the OP group ( P < 0.0001). Negative CK7 expression showed a potential impact on overall survival in early‐stage patients. In the RC group, the prevalence of cases with post‐therapeutic residual carcinoma cells was higher in the CK7‐negative group than in the positive group ( P = 0.003). We found that decreased expression of CK7 could be a prognostic factor in early‐stage cervical cancer patients. Conclusion: This result may provide strategies and suggestions for new treatment options and follow‐up practices in managing patients with cervical cancer.